Table 1 Clinical and serological features of the EA patients.
From: Increased disease activity in early arthritis patients with anti-carbamylated protein antibodies
Feature | EAa patients, |
|---|---|
n = 978 | |
Women, n (%) | 750 (76.7) |
Years, median (IQR)b | 52.2 (40.1–65.5) |
Weeks since onset, median (IQR)b | 16 (8–28) |
Calendar year of onset, median (IQR) | 2008 (2004–11) |
Smokers, n (%) | 412 (42.1) |
Classified as RA at 2 yearsc, n (%) | 505 (51.6) |
RF positive, n (%) | 416 (42.5) |
CCP positive, n (%) | 376 (38.4) |
ACarPA positive, n (%) | 275 (28.1) |
DAS28-ESR, median (IQR) | |
0 months | 4.4 (3.3–5.6) |
6 monthsb | 3.0 (2.3–4.0) |
12 monthsb | 3.1 (2.2–3.9) |
24 monthsb | 2.7 (2.1–3.7) |
DAS28-ESR components at baseline, median (IQR) | |
VAS pain | 47 (24–69) |
Patient global assessment | 4.5 (2.5–6.3) |
Physician global assessment | 3.5 (2.0–5.0) |
Tender joint count | 4 (1–9) |
Swollen joint count | 3 (1–7) |
ESR | 24 (13–44) |
HAQ, median (IQR) | |
0 months | 1.00 (0.50–1.63) |
6 monthsb | 0.38 (0.00–0.88) |
12 monthsb | 0.38 (0.00–0.88) |
24 monthsb | 0.38 (0.00–0.88) |
Initial treatmentb | |
Corticosteroids, n (%) | 223 (41.7) |
Methotrexate, n (%) | 327 (61.1) |
MTX dose, median (IQR) | 15 (10–15) |
Other csDMARDs, n (%) | 71 (13.3) |
Any of the drugsd, n (%) | 445 (83.2) |
Unmodified in the first 6 months, n (%) | 212 (39.6) |
